Back to News
Market Impact: 0.25

Validea Detailed Fundamental Analysis

EMRNDAQ
Company FundamentalsAnalyst InsightsCapital Returns (Dividends / Buybacks)Market Technicals & Flows
Validea Detailed Fundamental Analysis

Emerson Electric Co (EMR) has been rated 81% by Validea's Multi-Factor Investor model, based on Pim van Vliet's strategy, which prioritizes low volatility stocks exhibiting strong momentum and high net payout yields. This score signifies "some interest" in the large-cap growth stock, positioned within the Scientific & Technical Instruments industry, for investors employing a conservative factor investing approach.

Analysis

Emerson Electric Co. (EMR) scores 81% on Validea's Multi-Factor Investor model, which is based on Pim van Vliet’s conservative factor strategy favoring low-volatility stocks with strong momentum and high net payout yields. This score indicates moderate interest, as it surpasses the 80% threshold but remains below the 90% level for strong interest. The analysis reveals a mixed profile: EMR successfully passes the model's criteria for market capitalization and standard deviation, confirming its characteristics as a large-cap, low-volatility security. However, it receives only a 'NEUTRAL' rating for key return-driving factors, specifically its 'Twelve Minus One Momentum' and 'Net Payout Yield'. Critically, despite the 81% quantitative score, the stock's 'FINAL RANK' is designated as a 'FAIL', suggesting that its neutral performance on momentum and yield is insufficient to meet the strategy's holistic requirements for a full endorsement.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

mildly positive

Sentiment Score

0.30

Ticker Sentiment

EMR0.60
NDAQ0.00

Key Decisions for Investors

  • Investors employing low-volatility or conservative equity strategies should note EMR's favorable profile on risk metrics such as standard deviation, which aligns with the defensive component of the screened strategy.
  • Caution is warranted due to the stock's 'FAIL' on the model's final rank, driven by neutral ratings on momentum and net payout yield, indicating it does not currently meet all criteria for a robust multi-factor investment.
  • Portfolio managers should monitor EMR for any material improvement in its momentum profile or an increase in its net payout yield, as such changes could trigger a more positive signal from this quantitative model.